Grandview Asset Management LLC purchased a new position in shares of Charles River Laboratories Intl. Inc (NYSE:CRL) during the first quarter, Holdings Channel reports. The firm purchased 1,914 shares of the medical research company’s stock, valued at approximately $278,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Fort L.P. bought a new stake in shares of Charles River Laboratories Intl. during the fourth quarter worth approximately $27,000. Tompkins Financial Corp boosted its holdings in shares of Charles River Laboratories Intl. by 63.1% during the first quarter. Tompkins Financial Corp now owns 199 shares of the medical research company’s stock worth $27,000 after acquiring an additional 77 shares during the period. Riverview Trust Co bought a new stake in shares of Charles River Laboratories Intl. during the fourth quarter worth approximately $30,000. Sageworth Trust Co bought a new stake in shares of Charles River Laboratories Intl. during the first quarter worth approximately $37,000. Finally, Kwmg LLC boosted its holdings in shares of Charles River Laboratories Intl. by 32.4% during the fourth quarter. Kwmg LLC now owns 429 shares of the medical research company’s stock worth $49,000 after acquiring an additional 105 shares during the period. 93.90% of the stock is currently owned by hedge funds and other institutional investors.

CRL has been the subject of a number of research analyst reports. SunTrust Banks boosted their price objective on Charles River Laboratories Intl. to $151.00 and gave the stock a “buy” rating in a report on Thursday, February 14th. Jefferies Financial Group reiterated a “buy” rating and issued a $162.00 price target on shares of Charles River Laboratories Intl. in a research note on Thursday, February 14th. Barclays boosted their price target on Charles River Laboratories Intl. from $135.00 to $145.00 and gave the company an “equal weight” rating in a research note on Monday, March 18th. Zacks Investment Research upgraded Charles River Laboratories Intl. from a “sell” rating to a “hold” rating in a research note on Thursday, May 9th. Finally, Wolfe Research initiated coverage on Charles River Laboratories Intl. in a research note on Tuesday, April 2nd. They issued a “market perform” rating for the company. Seven analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $145.64.

In other Charles River Laboratories Intl. news, Director Stephen D. Chubb sold 4,540 shares of the firm’s stock in a transaction on Tuesday, February 19th. The stock was sold at an average price of $141.23, for a total value of $641,184.20. Following the sale, the director now owns 38,868 shares of the company’s stock, valued at approximately $5,489,327.64. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP William D. Barbo sold 8,155 shares of the firm’s stock in a transaction on Wednesday, February 27th. The shares were sold at an average price of $141.03, for a total value of $1,150,099.65. Following the completion of the sale, the vice president now directly owns 31,756 shares in the company, valued at approximately $4,478,548.68. The disclosure for this sale can be found here. In the last ninety days, insiders sold 36,570 shares of company stock worth $5,152,105. Company insiders own 1.80% of the company’s stock.

Shares of CRL stock traded up $1.34 during trading on Thursday, hitting $132.97. The company had a trading volume of 1,987 shares, compared to its average volume of 403,452. The company has a current ratio of 1.63, a quick ratio of 1.39 and a debt-to-equity ratio of 1.10. The stock has a market cap of $6.39 billion, a P/E ratio of 22.05, a price-to-earnings-growth ratio of 1.69 and a beta of 0.99. Charles River Laboratories Intl. Inc has a one year low of $102.96 and a one year high of $149.07.

Charles River Laboratories Intl. (NYSE:CRL) last released its earnings results on Tuesday, May 7th. The medical research company reported $1.40 earnings per share for the quarter, topping the consensus estimate of $1.38 by $0.02. The firm had revenue of $604.57 million during the quarter, compared to analysts’ expectations of $587.65 million. Charles River Laboratories Intl. had a return on equity of 23.03% and a net margin of 9.63%. The company’s quarterly revenue was up 22.4% on a year-over-year basis. During the same period in the prior year, the company earned $1.29 earnings per share. Analysts forecast that Charles River Laboratories Intl. Inc will post 6.47 EPS for the current year.

WARNING: “Grandview Asset Management LLC Purchases Shares of 1,914 Charles River Laboratories Intl. Inc (CRL)” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2019/05/16/grandview-asset-management-llc-purchases-shares-of-1914-charles-river-laboratories-intl-inc-crl.html.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Featured Story: What is the quiet period?

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories Intl. Inc (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.